Skip to content

Released Aug 15, 2022, after the close

10-Q filed Aug 15, 2022, 46 days after period end · 0001193125-22-221297

Q2 2022 · 10-Q
Revenue—
Net Income-$10.15MN/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.25N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$10,411,000N/M
Operating Cash Flowderived-$6,468,000N/M
Free Cash Flowderived-$6,504,000—

What the release said

The release

Same quarter

MetricQ2 2022Q2 2021Q2 2020
Net Income-$10.15M-$61.36M-$2.04M
EPS Diluted-$0.25-$141.93-$4.86

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR